SUMITOMO CHEMICAL

Sumitomo Chemical is engaged in the pharmaceuticals business mainly through its subsidiary Dainippon Sumitomo Pharma Co., Ltd., and Nihon Medi-Physics Co., Ltd., a radiopharmaceutical joint venture between Sumitomo Chemical and GE Healthcare, Ltd. The Company positions pharmaceuticals among its core businesses and is actively promoting the business in collaboration with group companies.

	Major group companies

Dainippon Sumitomo Pharma Co., Ltd.

Formulation Research

Pharmaceutial Products

Dainippon Sumitomo Pharma was formed in October 2005 through the merger of Dainippon Pharmaceuticals and Sumitomo Pharmaceutical, and aims to contribute the betterment of healthcare and fuller lives for all people worldwide, while striving to be a leading research-driven pharmaceutical company. The Company centers on its therapeutic pharmaceuticals business, capitalizing on the strengths of its four main products: Amlodin (therepeutic agent for hypertension and angina pectoris), Gasmotin (gastroprokinetic agent), Prorenal (agent for the improvement of peripheral circulation), and Meropen (carbapenem antibiotic). The Company also maintains a rich pipeline of drugs to meet a wide range of the medical community's needs for treatment in such areas as central nervous system disorders (CNS), diabetes, allergies, inflammatory and bone diseases, and cancer and infectious diseases. Leveraging the capabilities of over 1500 broadly experienced MRs allows the Company to fully cover the domestic market and provide in-depth information. Dainippon Sumitomo Pharma will strive to bring compounds at the clinical developmental stage to market within the shortest possible time frame in order to provide the medical establishment with effective remedies and treatments both domestically and abroad, and will continually strive to meet the challenge of gaining a worldwide reputation for excellence in the manufacture of advanced pharmaceuticals.

Nihon Medi-Physics Co., Ltd.

Thallium Chloride

Nihon Medi-Physics, established as a 50-50 joint venture by Sumitomo Chemical and GE Healthcare, is contributing to people's health through R&D, manufacture and supply of diagnostics indispensable for the early discovery of such diseases as cancer and chronic ailments that are becoming increasingly common in aging societies.
In vivo radio diagnostics, the company's major products, are used in highly specialized fields like nuclear medicine. By looking at images on a display showing radio diagnostics congregating to specific organs or tissues after being administered by special inspection equipment, the shape of an organ, blood circulation, metabolism, tumors if any, and other diagnostic information can be obtained.
The company is pursuing new business possibilities responding to needs in the medical care area based on a "consumer satisfaction" principle and for the benefit of an aging society.

Page top